Tianlei Ying

InstitutionFudan University
AddressShanghai
China
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 16 Covid-19 publications, with a maximum of 3 publications in February 2020
    All Publications
    Bar chart showing 73 publications over 13 distinct years, with a maximum of 12 publications in 2017
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Qu Y, Zhang X, Wang M, Sun L, Jiang Y, Li C, Wu W, Chen Z, Yin Q, Jiang X, Liu Y, Li C, Li J, Ying T, Li D, Zhan F, Wang Y, Guan W, Wang S, Liang M. Antibody Cocktail Exhibits Broad Neutralization Activity Against SARS-CoV-2 and SARS-CoV-2 Variants. Virol Sin. 2021 Oct; 36(5):934-947. PMID: 34224110.
      Citations: 3     Fields:    Translation:Humans
    2. Xiang R, Yu Z, Wang Y, Wang L, Huo S, Li Y, Liang R, Hao Q, Ying T, Gao Y, Yu F, Jiang S. Recent advances in developing small-molecule inhibitors against SARS-CoV-2. Acta Pharm Sin B. 2021 Jul 02. PMID: 34249607.
      Citations: 4     
    3. Zhu X, Yu F, Wu Y, Ying T. Potent germline-like monoclonal antibodies: rapid identification of promising candidates for antibody-based antiviral therapy. Antib Ther. 2021 Apr; 4(2):89-98. PMID: 34104872.
      Citations:    
    4. Ye F, Zhao J, Xu P, Liu X, Yu J, Shangguan W, Liu J, Luo X, Li C, Ying T, Wang J, Yu B, Wang P. Innentitelbild: Synthetic Homogeneous Glycoforms of the SARS-CoV-2 Spike Receptor-Binding Domain Reveals Different Binding Profiles of Monoclonal Antibodies (Angew. Chem. 23/2021). Angew Chem Weinheim Bergstr Ger. 2021 Jun 01; 133(23):12718. PMID: 34149107.
      Citations:    
    5. Ye F, Zhao J, Xu P, Liu X, Yu J, Shangguan W, Liu J, Luo X, Li C, Ying T, Wang J, Yu B, Wang P. Synthetic Homogeneous Glycoforms of the SARS-CoV-2 Spike Receptor-Binding Domain Reveals Different Binding Profiles of Monoclonal Antibodies. Angew Chem Int Ed Engl. 2021 06 01; 60(23):12904-12910. PMID: 33709491.
      Citations: 4     Fields:    Translation:HumansCells
    6. Li C, Tian X, Jia X, Wan J, Lu L, Jiang S, Lan F, Lu Y, Wu Y, Ying T. The impact of receptor-binding domain natural mutations on antibody recognition of SARS-CoV-2. Signal Transduct Target Ther. 2021 03 23; 6(1):132. PMID: 33758169.
      Citations: 11     Translation:HumansCells
    7. Zhou Y, Liu Z, Li S, Xu W, Zhang Q, Silva IT, Li C, Wu Y, Jiang Q, Liu Z, Wang Q, Guo Y, Wu J, Gu C, Cai X, Qu D, Mayer CT, Wang X, Jiang S, Ying T, Yuan Z, Xie Y, Wen Y, Lu L, Wang Q. Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. Cell Rep. 2021 02 02; 34(5):108699. PMID: 33485405.
      Citations: 25     Fields:    Translation:HumansCells
    8. Yi Z, Ling Y, Zhang X, Chen J, Hu K, Wang Y, Song W, Ying T, Zhang R, Lu H, Yuan Z. Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population. Emerg Microbes Infect. 2020 Dec; 9(1):1988-1996. PMID: 32844713.
      Citations: 16     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    9. Liu Z, Xu W, Xia S, Gu C, Wang X, Wang Q, Zhou J, Wu Y, Cai X, Qu D, Ying T, Xie Y, Lu L, Yuan Z, Jiang S. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduct Target Ther. 2020 11 27; 5(1):282. PMID: 33247109.
      Citations: 34     Translation:HumansAnimalsCellsPHPublic Health
    10. Yu F, Xiang R, Deng X, Wang L, Yu Z, Tian S, Liang R, Li Y, Ying T, Jiang S. Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. Signal Transduct Target Ther. 2020 09 22; 5(1):212. PMID: 32963228.
      Citations: 29     Translation:HumansCellsPHPublic Health
    11. Li Y, Lai DY, Zhang HN, Jiang HW, Tian X, Ma ML, Qi H, Meng QF, Guo SJ, Wu Y, Wang W, Yang X, Shi DW, Dai JB, Ying T, Zhou J, Tao SC. Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients. Cell Mol Immunol. 2020 10; 17(10):1095-1097. PMID: 32895485.
      Citations: 47     Fields:    Translation:HumansCellsPHPublic Health
    12. Wan J, Xing S, Ding L, Wang Y, Gu C, Wu Y, Rong B, Li C, Wang S, Chen K, He C, Zhu D, Yuan S, Qiu C, Zhao C, Nie L, Gao Z, Jiao J, Zhang X, Wang X, Ying T, Wang H, Xie Y, Lu Y, Xu J, Lan F. Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection. Cell Rep. 2020 07 21; 32(3):107918. PMID: 32668215.
      Citations: 59     Fields:    Translation:HumansCellsPHPublic Health
    13. Wu Y, Li C, Xia S, Tian X, Kong Y, Wang Z, Gu C, Zhang R, Tu C, Xie Y, Yang Z, Lu L, Jiang S, Ying T. Identification of Human Single-Domain Antibodies against SARS-CoV-2. Cell Host Microbe. 2020 06 10; 27(6):891-898.e5. PMID: 32413276.
      Citations: 89     Fields:    Translation:HumansCells
    14. Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, Lu L, Jiang S, Yang Z, Wu Y, Ying T. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020; 9(1):382-385. PMID: 32065055.
      Citations: 534     Fields:    Translation:HumansCells
    15. Xia S, Zhu Y, Liu M, Lan Q, Xu W, Wu Y, Ying T, Liu S, Shi Z, Jiang S, Lu L. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol. 2020 07; 17(7):765-767. PMID: 32047258.
      Citations: 201     Fields:    Translation:HumansCellsPHPublic Health
    16. Jiang S, Xia S, Ying T, Lu L. A novel coronavirus (2019-nCoV) causing pneumonia-associated respiratory syndrome. Cell Mol Immunol. 2020 05; 17(5):554. PMID: 32024976.
      Citations: 54     Fields:    Translation:HumansCellsPHPublic Health
    17. Wang L, Xu J, Kong Y, Liang R, Li W, Li J, Lu J, Dimitrov DS, Yu F, Wu Y, Ying T. Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV. Antibodies (Basel). 2019 Nov 04; 8(4). PMID: 31690009.
      Citations: 5     
    18. Liang R, Wang L, Zhang N, Deng X, Su M, Su Y, Hu L, He C, Ying T, Jiang S, Yu F. Development of Small-Molecule MERS-CoV Inhibitors. Viruses. 2018 12 17; 10(12). PMID: 30562987.
      Citations: 26     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    19. Fan C, Wu X, Liu Q, Li Q, Liu S, Lu J, Yang Y, Cao Y, Huang W, Liang C, Ying T, Jiang S, Wang Y. A Human DPP4-Knockin Mouse's Susceptibility to Infection by Authentic and Pseudotyped MERS-CoV. Viruses. 2018 08 23; 10(9). PMID: 30142928.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    20. Jin Y, Lei C, Hu D, Dimitrov DS, Ying T. Human monoclonal antibodies as candidate therapeutics against emerging viruses. Front Med. 2017 Dec; 11(4):462-470. PMID: 29159596.
      Citations: 24     Fields:    Translation:Humans
    21. van Doremalen N, Falzarano D, Ying T, de Wit E, Bushmaker T, Feldmann F, Okumura A, Wang Y, Scott DP, Hanley PW, Feldmann H, Dimitrov DS, Munster VJ. Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets. Antiviral Res. 2017 07; 143:30-37. PMID: 28389142.
      Citations: 33     Fields:    Translation:AnimalsCells
    22. Agrawal AS, Ying T, Tao X, Garron T, Algaissi A, Wang Y, Wang L, Peng BH, Jiang S, Dimitrov DS, Tseng CT. Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection. Sci Rep. 2016 08 19; 6:31629. PMID: 27538452.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    23. Houser KV, Gretebeck L, Ying T, Wang Y, Vogel L, Lamirande EW, Bock KW, Moore IN, Dimitrov DS, Subbarao K. Prophylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)-Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection. J Infect Dis. 2016 May 15; 213(10):1557-61. PMID: 26941283.
      Citations: 38     Fields:    Translation:HumansAnimalsCells
    24. Ying T, Prabakaran P, Du L, Shi W, Feng Y, Wang Y, Wang L, Li W, Jiang S, Dimitrov DS, Zhou T. Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody. Nat Commun. 2015 Sep 15; 6:8223. PMID: 26370782.
      Citations: 59     Fields:    Translation:HumansCells
    25. Dimitrov DS, Jiang S, Ying T, Tseng CT, Zhang L, Yuen KY. No evidence for a superior platform to develop therapeutic antibodies rapidly in response to MERS-CoV and other emerging viruses. Proc Natl Acad Sci U S A. 2015 Sep 15; 112(37):E5115. PMID: 26318165.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    26. Ying T, Li W, Dimitrov DS. Discovery of T-Cell Infection and Apoptosis by Middle East Respiratory Syndrome Coronavirus. J Infect Dis. 2016 Mar 15; 213(6):877-9. PMID: 26203059.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    27. Lu L, Xia S, Ying T, Jiang S. Urgent development of effective therapeutic and prophylactic agents to control the emerging threat of Middle East respiratory syndrome (MERS). Emerg Microbes Infect. 2015 Jun 17; 4:e37. PMID: 26954884.
      Citations: 6     Fields:    Translation:HumansCells
    28. Ying T, Li H, Lu L, Dimitrov DS, Jiang S. Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections. Microbes Infect. 2015 Feb; 17(2):142-8. PMID: 25456101.
      Citations: 24     Fields:    Translation:HumansCellsPHPublic Health
    29. Xia S, Liu Q, Wang Q, Sun Z, Su S, Du L, Ying T, Lu L, Jiang S. Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. Virus Res. 2014 Dec 19; 194:200-10. PMID: 25451066.
      Citations: 46     Fields:    Translation:HumansCells
    30. Ying T, Du L, Ju TW, Prabakaran P, Lau CC, Lu L, Liu Q, Wang L, Feng Y, Wang Y, Zheng BJ, Yuen KY, Jiang S, Dimitrov DS. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol. 2014 Jul; 88(14):7796-805. PMID: 24789777.
      Citations: 107     Fields:    Translation:HumansCells
    Ying's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (202)
    Explore
    _
    Co-Authors (188)
    Explore
    _
    Similar People (60)
    Explore
    _